

Status of the Quantitative Imaging Profile

Lung Nodule Volume Assessment
and Monitoring in Low Dose CT Screening

Prevent Cancer Foundation
Quantitative Imaging Workshop XIII
June 13-14, 2016



David S. Gierada, MD
Washington University
Professor of Radiology
QIBA Working Group Co-Chair



QIBA



Goal

- Advance the science and implementation of quantitative imaging in clinical trials and practice
 - Use imaging devices as automated, reproducible measurement systems for specific tasks

QIBA



Approach

- Conduct rigorous assessment of the variability inherent in image-based measurements
- Determine performance capabilities of specific imaging biomarkers and requirements for achieving them

QIBA Biomarker Committees



- CT Volumetry
- FDG-PET
- PET Amyloid
- SPECT
- CT Lung Density
- fMRI
- MR Elastography
- Ultrasound Shear Wave Speed
- Ultrasound Volume Blood Flow

QIBA



Collaboration

- Imaging science experts (physicists, engineers, image processing scientists)
- Biostatisticians and metrologists
- Physicians
- Biologists, chemists
- Manufacturers
- Regulators
- Patient advocates

The QIBA Profile



Describes measurement performance achievable and conditions required

- Claims
- Specifications
- Assessment Procedures


QIBA





Activities

- Literature review
- Groundwork studies
- Clinical trial data analysis
- Theoretical analysis and simulations
- Discussion and expert consensus

CT Volumetry



VS.



Advantages :

- Independent of lesion and measurement orientation
- Independent of selected slice and orientation
- Sensitive to size change in all directions
- Reproducible

CT Volumetry Biomarker Committee Profiles

- Change Measurements in Solid Tumors (Lung ≥ 10 mm)
 - Publicly reviewed 2011
(http://qibawiki.rsna.org/images/e/e3/2011_07_28_Profile_CT_Advanced_Disease_V2_0f.pdf)
 - Updated version in progress, liver lesions being addressed
- **Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening**
 - Released for Public Comment 6/2/16-8/1/16
 - Open at http://qibawiki.rsna.org/index.php/Work_Product_for_Review

Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening

Claim 1

Nodule Volume

- 95% confidence interval = $\pm(\text{measured volume} \times 1.96 \times \text{CV})$

Nodule Diameter (mm)	Nodule Volume (mm ³)	Coefficient of Variation (CV)	95% Confidence Interval
≥ 6 and < 8 mm	≥ 113 and < 268	0.29	$\pm 57\%$
≥ 8 and < 10 mm	≥ 268 and < 524	0.19	$\pm 37\%$
≥ 10 and < 12 mm	≥ 524 and < 905	0.14	$\pm 27\%$
≥ 12 mm	> 905	0.11	$\pm 22\%$

Claim 1 Examples

Nodule Volume

Nodule volume	CV	95% CI	Corresponding diameter	95% CI (diameter)
150 mm ³	0.29	65-235 mm ³	6.6 mm	5.0-7.6 mm
500 mm ³	0.19	314-686 mm ³	9.8 mm	8.4-11.0 mm
800 mm ³	0.14	580-1020 mm ³	11.5 mm	10.4-12.4 mm

Calculator at <http://www.accumetra.com/NoduleCalculator.html>

- Currently for investigational use only

Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening

Claim 2

Change in Nodule Volume (95% confidence)

- Real if measured %change > $2.77 \times CV1 \times 100$
- Amount of change $\pm 1.96 \times \sqrt{[Y_1 \times CV1]^2 + [Y_2 \times CV2]^2}$

Nodule Diameter (mm)	Nodule Volume (mm ³)	Coefficient of Variation (CV)	% Change Required
≥ 6 and < 8 mm	≥ 113 and < 268	0.29	80%
≥ 8 and < 10 mm	≥ 268 and < 524	0.19	53%
≥ 10 and < 12 mm	≥ 524 and < 905	0.14	39%
≥ 12 mm	> 905	0.11	30%

Claim 2 Examples

% Change in Volume

Change	% Change	Min required ($2.77 \times CV \times 100$)	Real change? (95% confidence)
524 - 917 mm ³ (10.0 - 12.0 mm)	75% (20%)	$2.77 \times 0.14 \times 100 =$ 39%	Yes (149-637 mm ³)
180 - 270 mm ³ (7.0-8.0 mm)	50% (14%)	$2.77 \times 0.29 \times 100 =$ 80%	Uncertain




Calculator at <http://www.accumetra.com/NoduleCalculator.html>

- Currently for investigational use only





Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening Profile Conditions

- Solid nodules close to spherical (shortest dimension is at least 60% of longest dimension)
- Nodule segmented without manual editing
- Subject handling, acquisition, reconstruction, analysis specifications followed
- Volume: Zero measurement bias and covariance
- Change: Measurement system components same at both time points
- CT scanner meets conformance requirements


Solid, Spherical, Isolated



Attached, Non-spherical



Subsolid/Ground Glass Semisolid/Mixed



Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening Specifications

- **Subject selection and handling**
 - Symptoms, positioning, breath holding
- **Image Data Acquisition**
 - kVp, mAs, collimation, pitch
- **Image Data Reconstruction**
 - Slice thickness and interval, kernel
- **Image analysis**
 - Software, reading paradigm

Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening

Assessment Procedures

- **CT Equipment**
 - ACR and manufacturer guidelines
- **Technologist, Radiologist, Image Analyst**
 - ACR guidelines, relevant training
- **Image Analysis Software**
 - TBD

QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening

Post-comment period

http://qibawiki.rsna.org/index.php/Work_Product_for_Review

- Address issues raised and finalize
- Verify in practice and modify as needed
- Update with technical improvements
- Assess clinical value


Acknowledgements

- Profile Co-Chairs: Sam Armato and Jim Mulshine
- Claims: Rick Avila, Nancy Obuchowski, David Yankelevitz
- CT Coordinating Committee and CT Volumetry Biomarker Committee (QIBA wiki)
- Dan Sullivan, Ed Jackson, and QIBA Leadership
- RSNA Staff: Fiona Miller, Joe Koudelik, Julie Lisiecki, Susan Weinmann



Thank You!

Quantitative
Imaging
Biomarkers
Alliance



 Washington
University in St. Louis
SCHOOL OF MEDICINE
 Mallinckrodt Institute
of Radiology



